ContraFect Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update March 14, 2019
ContraFect Announces $6.94 Million in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-negative ESKAPE Pathogens March 4, 2019
ContraFect Announces Oral Presentation at the 2019 Gordon Research Conference on Mechanisms and Application: Realizing the Potential of Antimicrobial Host Defense Peptides for Human and Veterinary Medicine February 13, 2019
ContraFect Announces Additional $2.3 Million in Funding from CARB-X to Support Gram-Negative Lysin Program January 17, 2019
ContraFect’s Exebacase (CF-301) Improved Clinical Outcomes in Staphylococcus aureus Bacteremia including  Right-Sided Endocarditis Compared to Standard of Care Antibiotics Alone in a First-in-Patient Phase 2 Superiority Study January 7, 2019
